Researchers are looking at the effects of medical interventions on pathogens like bacteria and viruses that cause them to mutate more frequently in terms of evolution. An investigation into mutation rates became a concern after several concerns were raised on social media following the coronavirus pandemic.
Evolutionary Safety: Drug Increases Mutation Rate
A new study examined how mutations could affect the virus after Molnupiravir introduced a new approach to fighting COVID-19. There were concerns that the virus could mutate, and instead of self-destructing, it could develop into a worse version.
Molnupiravir causes the SARS-CoV-2 virus to mutate rapidly, causing it to self-destruct. Although it proved to be a successful treatment, there were worries that it would unintentionally lead to the emergence of more harmful virus strains.
In response to these worries, a group headed by professors Martin A. Nowak of Harvard University and Yitzhak Pilpel of the Weizmann Institute of Science examined these treatments' evolutionary safety. They suggested three approaches to evaluate evolutionary safety -- (1) using theoretical mathematical models, (2) integrating it into clinical trials, and (3) doing lab experiments.
Their findings suggested that Molnupiravir may have a dual benefit in treating coronavirus infections and preventing the emergence of potentially harmful new strains. In addition to lowering hospitalization rates and viral load, the medication raised the mutation rate during viral replication from one to two or three per million.
Although medication may cause more mutations, the evolutionary risk is minimal if it dramatically reduces the viral population. But this delicate balance also depends on other elements, like the patient's immune system strength and the treatment's timing.
The study emphasizes that to design and implement therapies that change the rates of pathogen mutation, a thorough grasp of the biology and evolutionary processes involved is essential.
What is Molnupiravir?
Molnupiravir is an oral prodrug of beta-D-N4-hydroxycytidine (NHC), a ribonucleoside that has demonstrated antiviral activity against SARS-CoV-2 in vitro and in specific clinical trials. Lethal mutagenesis and viral mutations are caused by the absorption of NHC by viral RNA-dependent RNA polymerases.
For the treatment of adults with mild to moderate COVID-19 who are within five days of symptom onset, who are at high risk of developing a severe illness, and for whom alternative antiviral therapies are not available or clinically appropriate, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Molnupiravir on Dec. 23, 2021. The drug is anticipated to be effective against the Omicron variant and its subvariants.
Molnupiravir poses a theoretical danger of causing mutations in human host cells due to its ability to be digested and integrated into host DNA, making it a mutagenic ribonucleoside antiviral drug. It has been tested in two in vivo assays for mutagenicity in rodents.
One study yielded inconclusive findings. However, there was no evidence of mutagenicity in the other research.
The FDA concluded that Molnupiravir had a low risk of genotoxicity based on the existing genotoxicity data and the 5-day treatment period. Furthermore, the FDA has mandated that the producer keep an eye on genomic databases for the appearance of SARS-CoV-2 variants due to concerns regarding Molnupiravir's possible impact on SARS-CoV-2 mutation rates.
RELATED ARTICLE: Long COVID Treatment: Will Pfizer's Paxlovid Finally Solve Today's Global Pandemic?
Check out more news and information on COVID-19 in Science Times.
